[HTML][HTML] Targeting Akt in cancer for precision therapy
H Hua, H Zhang, J Chen, J Wang, J Liu… - Journal of Hematology & …, 2021 - Springer
Biomarkers-guided precision therapeutics has revolutionized the clinical development and
administration of molecular-targeted anticancer agents. Tailored precision cancer therapy …
administration of molecular-targeted anticancer agents. Tailored precision cancer therapy …
STING pathway agonism as a cancer therapeutic
The fact that a subset of human cancers showed evidence for a spontaneous adaptive
immune response as reflected by the T cell‐inflamed tumor microenvironment phenotype …
immune response as reflected by the T cell‐inflamed tumor microenvironment phenotype …
TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKɛ supports the anabolic demands of dendritic cell activation
B Everts, E Amiel, SCC Huang, AM Smith… - Nature …, 2014 - nature.com
The ligation of Toll-like receptors (TLRs) leads to rapid activation of dendritic cells (DCs).
However, the metabolic requirements that support this process remain poorly defined. We …
However, the metabolic requirements that support this process remain poorly defined. We …
The PI3K/AKT/mTOR interactive pathway
T Ersahin, N Tuncbag, R Cetin-Atalay - Molecular BioSystems, 2015 - pubs.rsc.org
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR)
signalling pathway is hyperactivated or altered in many cancer types and regulates a broad …
signalling pathway is hyperactivated or altered in many cancer types and regulates a broad …
HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity
Sensing cytosolic DNA through the cGAS–STING pathway constitutes a widespread innate
immune mechanism to monitor cellular damage and microbial invasion. Evading this …
immune mechanism to monitor cellular damage and microbial invasion. Evading this …
Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes
DW Shen, LM Pouliot, MD Hall, MM Gottesman - Pharmacological reviews, 2012 - ASPET
Cisplatin is one of the most effective broad-spectrum anticancer drugs. Its effectiveness
seems to be due to the unique properties of cisplatin, which enters cells via multiple …
seems to be due to the unique properties of cisplatin, which enters cells via multiple …
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks
B Magnuson, B Ekim, DC Fingar - Biochemical Journal, 2012 - portlandpress.com
The ribosomal protein S6K (S6 kinase) represents an extensively studied effector of the
TORC1 [TOR (target of rapamycin) complex 1], which possesses important yet incompletely …
TORC1 [TOR (target of rapamycin) complex 1], which possesses important yet incompletely …
[HTML][HTML] The role of TBK1 in cancer pathogenesis and anticancer immunity
The TANK-binding kinase 1 (TBK1) is a serine/threonine kinase belonging to the non-
canonical inhibitor of nuclear factor-κB (IκB) kinase (IKK) family. TBK1 can be activated by …
canonical inhibitor of nuclear factor-κB (IκB) kinase (IKK) family. TBK1 can be activated by …
[HTML][HTML] TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation
Autophagy is a fundamental biological process of the eukaryotic cell contributing to diverse
cellular and physiological functions including cell-autonomous defense against intracellular …
cellular and physiological functions including cell-autonomous defense against intracellular …
mTOR complex 2 signaling and functions
WJ Oh, E Jacinto - Cell cycle, 2011 - Taylor & Francis
The mechanistic target of rapamycin (mTOR) plays a central role in cellular growth and
metabolism. mTOR forms two distinct protein complexes, mTORC1 and mTORC2. Much is …
metabolism. mTOR forms two distinct protein complexes, mTORC1 and mTORC2. Much is …